Furthermore, the synergistic cytotoxicity of breast cancer cells observed under HSP70 inhibitor and doxorubicin co-treatment detailed in this study may provide a feasible strategy for future preclinical studies, particularly for evaluating the toxic effects on normal cardiac cells. Here, HSPA1A is linked to breast carcinoma.